Publications
Publications
- January 2021
- HBS Case Collection
Takeda Pharmaceutical Company Limited (A)
By: David J. Collis, Nobuo Sato and Akiko Kanno
Abstract
This case follows Christophe Weber, President and CEO of Takeda Pharmaceutical Company Limited, a leading pharmaceutical company headquartered in Tokyo, Japan, as Takeda considers acquiring Shire Plc, a biotech company based in Ireland. The acquisition would turn Takeda into a top ten global pharmaceutical company; however, other pharma companies were showing initial interest in acquiring Shire, and the acquisition would require a large amount of funding. Other concerns about the bid were nonfinancial. Over the last two decades, Takeda had aggressively pursued globalization and was now a global company with two thirds of revenue raised outside Japan and a diverse management team. What was the implication of acquiring Shire? Was now the right time to take such a big step? Was the acquisition in line with the company’s goals? How would the combined company be managed? Would the acquisition put an end to Takeda as a Japanese company?
Keywords
Pharmaceutical Companies; Pharmaceutical Industry; Pharmaceuticals; Japan; Biotech; Biotechnology; M＆a; Mergers ＆ Acquisitions; Globalization; Management; Asia; R＆d; Talent Management; Mergers And Acquisitions; Globalization; Global Strategy; Pharmaceutical Industry; Biotechnology Industry; Japan
Citation
Collis, David J., Nobuo Sato, and Akiko Kanno. "Takeda Pharmaceutical Company Limited (A)." Harvard Business School Case 721-373, January 2021.
About The Author
